GLP-1 Medical Weight Loss (Semaglutide / Tirzepatide)

Dr Edwin Lim prescribes and supervises GLP-1 and GLP-1/GIP receptor agonist injections — semaglutide, tirzepatide, and liraglutide — for medically supervised weight management with transparent monthly pricing and regular clinical follow-up.

GLP-1 (glucagon-like peptide-1) receptor agonists have transformed medically supervised weight management over the past decade, and Edwin Lim Medical Aesthetic Clinic offers a transparent, physician-supervised programme using three classes of medication: daily liraglutide (Saxenda), once-weekly standard-dose semaglutide, once-weekly high-dose semaglutide (Wegovy equivalent), and once-weekly tirzepatide (a dual GLP-1/GIP agonist). GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which is released from the gut after meals. They slow gastric emptying, reduce appetite by acting on the hypothalamic satiety centres, and — in the case of tirzepatide — also activate GIP receptors that modulate fat storage and energy metabolism. Clinical trials (STEP and SURMOUNT programmes) have demonstrated average weight reductions of 10–22% of body weight over 68 weeks depending on the agent and dose. At Edwin Lim Medical Aesthetic Clinic, the programme begins with a medical consultation to assess baseline health markers, contraindications (personal or family history of thyroid cancer, pancreatitis, or MEN2), and suitability for GLP-1 therapy. Patients are started on the lowest effective dose and titrated up over 4–20 weeks to minimise gastrointestinal side effects (nausea, vomiting). Monthly follow-up appointments monitor weight, blood pressure, and any side effects, with dose adjustments as required. Patients are counselled that GLP-1 therapy works best in combination with dietary modification and regular physical activity, and the clinic provides lifestyle guidance alongside the prescription programme. The use of transparent pricing — rare among Singapore aesthetic clinics — is a hallmark of Dr Lim's practice approach.